Asset Details
Do you wish to reserve the book?
Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma
Do you wish to request the book?
Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma
2022
Overview
This study aimed whether the uptake of amino tracer positron emission tomography (PET) can be used as an additional imaging biomarker to estimate the prognosis of glioma. Participants comprised 56 adult patients with newly diagnosed and untreated World Health Organization (WHO) grade II–IV astrocytic glioma who underwent surgical excision and were evaluated by 11C-methionine PET prior to the surgical excision at Osaka City University Hospital from July 2011 to March 2018. Clinical and imaging studies were retrospectively reviewed based on medical records at our institution. Preoperative Karnofsky Performance Status (KPS) only influenced progression-free survival (hazard ratio [HR] 0.20; 95% confidence interval [CI] 0.10–0.41,
p
< 0.0001), whereas histology (anaplastic astrocytoma: HR 5.30, 95% CI 1.23–22.8,
p
= 0.025; glioblastoma: HR 11.52, 95% CI 2.27–58.47,
p
= 0.0032), preoperative KPS ≥ 80 (HR 0.23, 95% CI 0.09–0.62,
p
= 0.004), maximum lesion-to-contralateral normal brain tissue (LN max) ≥ 4.03 (HR 0.24, 95% CI 0.08–0.71,
p
= 0.01), and isocitrate dehydrogenase
(IDH)
status (HR 14.06, 95% CI 1.81–109.2,
p
= 0.011) were factors influencing overall survival (OS) in multivariate Cox regression. OS was shorter in patients with LN max ≥ 4.03 (29.3 months) than in patients with LN max < 4.03 (not reached;
p
= 0.03). OS differed significantly between patients with
IDH
mutant/LN max < 4.03 and patients with
IDH
mutant/LN max ≥ 4.03. LN max using 11C-methionine PET may be used in prognostic markers for newly identified and untreated WHO grade II–IV astrocytic glioma.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Astrocytoma - diagnostic imaging
/ Biomarkers, Tumor - metabolism
/ Brain Neoplasms - diagnostic imaging
/ Brain Neoplasms - metabolism
/ Female
/ Glioma
/ Humanities and Social Sciences
/ Humans
/ Male
/ Mutants
/ Patients
/ Positron emission tomography
/ Positron-Emission Tomography - methods
/ Science
/ Survival
